Target toxicity design for phase I dose-finding

DOI10.1080/24754269.2020.1800331MaRDI QIDQ5880075zbMATH OpenOpenAlexFDO

Authors Wenchuan Guo, Bob Zhong

Publication date 7 March 2023

Published in Statistical Theory and Related Fields (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/24754269.2020.1800331

zbMATH Keywords

dose-findinggroup-sequential-like designsMTDphase Ipowerrecommended phase II doses

Mathematics Subject Classification ID

Statistics (62-XX)

Cites work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Cumulative cohort design for dose-finding
• Design efficiency in dose finding studies
• scientific article; zbMATH DE number 1348603 (Why is no real title available?)
• Operating characteristics of the standard phase I clinical trial design.
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Cited in

(2)

• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs

This page was built for publication: Target toxicity design for phase I dose-finding

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5880075)